Publicaciones en colaboración con investigadores/as de University of Texas Southwestern Medical Center (5)

2019

  1. Cardiovascular risk reduction with once-weekly semaglutide in subjects with type 2 diabetes: A post hoc analysis of gender, age, and baseline CV risk profile in the SUSTAIN 6 trial

    Cardiovascular Diabetology, Vol. 18, Núm. 1

  2. Comparative efficacy, safety, and cardiovascular outcomes with once-weekly subcutaneous semaglutide in the treatment of type 2 diabetes: Insights from the SUSTAIN 1–7 trials

    Diabetes and Metabolism, Vol. 45, Núm. 5, pp. 409-418

2018

  1. Insulin degludec/liraglutide (IDegLira) was effective across a range of dysglycaemia and body mass index categories in the DUAL V randomized trial

    Diabetes, Obesity and Metabolism, Vol. 20, Núm. 1, pp. 200-205

2016

  1. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes

    New England Journal of Medicine, Vol. 375, Núm. 19, pp. 1834-1844

2015

  1. Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes

    New England Journal of Medicine, Vol. 373, Núm. 3, pp. 232-242